United States United States Non-Invasive Prenatal Testing Market

United States Non-Invasive Prenatal Testing Comprehensive Study by Type (High & Average Risk, Low Risk), Application (0-12 weeks, 13-24 weeks, 25-36 weeks), Consumables (Assay Kits & Reagents, Disposables), Instruments (Ultrasound Devices, Next-Generation Sequencing Systems, Polymerase Chain Reaction Instruments, Microarrays, Other Instruments), Testing (MaterniT21 PLUS, NIFTY, Harmony test, PrenaTest, Panorama test, Verifi, Others)

United States Non-Invasive Prenatal Testing Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
United States Non-Invasive Prenatal Testing Market Scope
Non-Invasive Prenatal Testing (NIPT) is a medical procedure employed during pregnancy to screen for specific genetic conditions in a developing fetus, all without the necessity for invasive methods like amniocentesis or chorionic villus sampling (CVS). NIPT typically involves the collection of a blood sample from the expectant mother and, in certain instances, a small DNA sample from the placenta. The primary objective of NIPT is the early detection of chromosomal abnormalities, encompassing conditions such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). Growing adoption of Non-Invasive Prenatal Testing (NIPT) due to its ability of high accuracy and early detection is a high impact rendering market driver. In addition, increased awareness about prenatal testing and its benefits, coupled with growing acceptance among expectant parents and healthcare providers, is driving the market growth.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledGE Healthcare (United States), Illumina, Inc. (United States), Thermo Fisher Scientific, Inc.(United States), Perkinelmer, Inc. (United States), Sequenom Laboratories (United States), Natera Inc. (United States), LabCorp (United States), Ivitae (United Status), Agilent Technologies, Inc.(United States) and Quest Diagnostics Incorporation (United States)
CAGR%


The market is highly intense and fragmented with International and Regional market players. Several Companies and Research Oganizations have signed distribution agreements with test providers to be able to offer advanced products and services to the patients, which is creating a positive impact on the Global Non-Invasive Prenatal Testing market.

GE Healthcare (United States), Illumina, Inc. (United States), Thermo Fisher Scientific, Inc.(United States), Perkinelmer, Inc. (United States), Sequenom Laboratories (United States), Natera Inc. (United States), LabCorp (United States), Ivitae (United Status), Agilent Technologies, Inc.(United States) and Quest Diagnostics Incorporation (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of North America United States Non-Invasive Prenatal Testing market by Type , by Application (0-12 weeks, 13-24 weeks and 25-36 weeks) and Region with country level break-up.

On the basis of geography, the market of United States Non-Invasive Prenatal Testing has been segmented into . region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In February 2019, Invitae launched Non-Invasive Prenatal Screening offers integrated testing using the two most common prenatal genetic tests, with in-depth follow-up testing available for patients who need it. The company made the announcement in conjunction with the Society for Maternal-Fetal Medicine.
In January 2023, GE Healthcare disclosed an agreement to acquire IMACTIS, a move aimed at bolstering its capabilities in interventional guidance. This acquisition is anticipated to open up substantial growth prospects for the IMACTIS CT-Navigation system, leveraging GE Healthcare's extensive installed base and global reach


Influencing Trend:
The increasing number of Partnerships and Collaborations focused on innovative Genetic solution analysis, to support the education program, and for the better price and faster availability of tests and Less delineation between High and Average risk, which is expected to enhance the volumetric capabilities of the market.

Market Growth Drivers:
Increasing Incidence of Chromosome Syndrome and Genetic Abnormalities, Rising Healthcare Expenditure, Growing Demand for Early and Non-Invasive Fetal Testing Procedures and High Number of Reported Late Pregnancies.

Challenges:
Reliability of Test Results Especially in Obese Women

Restraints:
Lack of Skilled Professionals and Cost Factor Associated with the Treatment.

Opportunities:
Accelerated customer adoption of NIPT procedures coupled with the expansion in the Distribution services of the operating entities

Key Target Audience
Non-Invasive Prenatal Testing Manufacturers, Government & Regulatory Agencies, Potential Investors, Research Organizations and Pharamaceutical Companies

Report Objectives / Segmentation Covered

By Type
  • High & Average Risk
  • Low Risk
By Application
  • 0-12 weeks
  • 13-24 weeks
  • 25-36 weeks
By Consumables
  • Assay Kits & Reagents
  • Disposables

By Instruments
  • Ultrasound Devices
  • Next-Generation Sequencing Systems
  • Polymerase Chain Reaction Instruments
  • Microarrays
  • Other Instruments

By Testing
  • MaterniT21 PLUS
  • NIFTY
  • Harmony test
  • PrenaTest
  • Panorama test
  • Verifi
  • Others

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Increasing Incidence of Chromosome Syndrome and Genetic Abnormalities
        • 3.2.2. Rising Healthcare Expenditure
        • 3.2.3. Growing Demand for Early and Non-Invasive Fetal Testing Procedures
        • 3.2.4. High Number of Reported Late Pregnancies.
      • 3.3. Market Challenges
        • 3.3.1. Reliability of Test Results Especially in Obese Women
      • 3.4. Market Trends
        • 3.4.1. The increasing number of Partnerships and Collaborations focused on innovative Genetic solution analysis, to support the education program, and for the better price and faster availability of tests
        • 3.4.2. Less delineation between High and Average risk, which is expected to enhance the volumetric capabilities of the market.
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. North America United States Non-Invasive Prenatal Testing, by Type, Application, Consumables, Instruments and Testing (value) (2017-2022)
      • 5.1. Introduction
      • 5.2. North America United States Non-Invasive Prenatal Testing (Value)
        • 5.2.1. North America United States Non-Invasive Prenatal Testing by: Type (Value)
          • 5.2.1.1. High & Average Risk
          • 5.2.1.2. Low Risk
        • 5.2.2. North America United States Non-Invasive Prenatal Testing by: Application (Value)
          • 5.2.2.1. 0-12 weeks
          • 5.2.2.2. 13-24 weeks
          • 5.2.2.3. 25-36 weeks
        • 5.2.3. North America United States Non-Invasive Prenatal Testing by: Consumables (Value)
          • 5.2.3.1. Assay Kits & Reagents
          • 5.2.3.2. Disposables
        • 5.2.4. North America United States Non-Invasive Prenatal Testing by: Instruments (Value)
          • 5.2.4.1. Ultrasound Devices
          • 5.2.4.2. Next-Generation Sequencing Systems
          • 5.2.4.3. Polymerase Chain Reaction Instruments
          • 5.2.4.4. Microarrays
          • 5.2.4.5. Other Instruments
        • 5.2.5. North America United States Non-Invasive Prenatal Testing by: Testing (Value)
          • 5.2.5.1. MaterniT21 PLUS
          • 5.2.5.2. NIFTY
          • 5.2.5.3. Harmony test
          • 5.2.5.4. PrenaTest
          • 5.2.5.5. Panorama test
          • 5.2.5.6. Verifi
          • 5.2.5.7. Others
    • 6. United States Non-Invasive Prenatal Testing: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2022)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. GE Healthcare (United States)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. Illumina, Inc. (United States)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. Thermo Fisher Scientific, Inc.(United States)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. Perkinelmer, Inc. (United States)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. Sequenom Laboratories (United States)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. Natera Inc. (United States)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. LabCorp (United States)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. Ivitae (United Status)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. Agilent Technologies, Inc.(United States)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. Quest Diagnostics Incorporation (United States)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
    • 7. North America United States Non-Invasive Prenatal Testing Sale, by Type, Application, Consumables, Instruments and Testing (value) (2023-2028)
      • 7.1. Introduction
      • 7.2. North America United States Non-Invasive Prenatal Testing (Value)
        • 7.2.1. North America United States Non-Invasive Prenatal Testing by: Type (Value)
          • 7.2.1.1. High & Average Risk
          • 7.2.1.2. Low Risk
        • 7.2.2. North America United States Non-Invasive Prenatal Testing by: Application (Value)
          • 7.2.2.1. 0-12 weeks
          • 7.2.2.2. 13-24 weeks
          • 7.2.2.3. 25-36 weeks
        • 7.2.3. North America United States Non-Invasive Prenatal Testing by: Consumables (Value)
          • 7.2.3.1. Assay Kits & Reagents
          • 7.2.3.2. Disposables
        • 7.2.4. North America United States Non-Invasive Prenatal Testing by: Instruments (Value)
          • 7.2.4.1. Ultrasound Devices
          • 7.2.4.2. Next-Generation Sequencing Systems
          • 7.2.4.3. Polymerase Chain Reaction Instruments
          • 7.2.4.4. Microarrays
          • 7.2.4.5. Other Instruments
        • 7.2.5. North America United States Non-Invasive Prenatal Testing by: Testing (Value)
          • 7.2.5.1. MaterniT21 PLUS
          • 7.2.5.2. NIFTY
          • 7.2.5.3. Harmony test
          • 7.2.5.4. PrenaTest
          • 7.2.5.5. Panorama test
          • 7.2.5.6. Verifi
          • 7.2.5.7. Others
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. United States Non-Invasive Prenatal Testing: by Type(USD Million)
    • Table 2. United States Non-Invasive Prenatal Testing: by Application(USD Million)
    • Table 3. United States Non-Invasive Prenatal Testing: by Consumables(USD Million)
    • Table 4. United States Non-Invasive Prenatal Testing: by Instruments(USD Million)
    • Table 5. United States Non-Invasive Prenatal Testing: by Testing(USD Million)
    • Table 6. Company Basic Information, Sales Area and Its Competitors
    • Table 7. Company Basic Information, Sales Area and Its Competitors
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Company Basic Information, Sales Area and Its Competitors
    • Table 16. United States Non-Invasive Prenatal Testing: by Type(USD Million)
    • Table 17. United States Non-Invasive Prenatal Testing: by Application(USD Million)
    • Table 18. United States Non-Invasive Prenatal Testing: by Consumables(USD Million)
    • Table 19. United States Non-Invasive Prenatal Testing: by Instruments(USD Million)
    • Table 20. United States Non-Invasive Prenatal Testing: by Testing(USD Million)
    • Table 21. Research Programs/Design for This Report
    • Table 22. Key Data Information from Secondary Sources
    • Table 23. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. North America United States Non-Invasive Prenatal Testing: by Type USD Million (2017-2022)
    • Figure 5. North America United States Non-Invasive Prenatal Testing: by Application USD Million (2017-2022)
    • Figure 6. North America United States Non-Invasive Prenatal Testing: by Consumables USD Million (2017-2022)
    • Figure 7. North America United States Non-Invasive Prenatal Testing: by Instruments USD Million (2017-2022)
    • Figure 8. North America United States Non-Invasive Prenatal Testing: by Testing USD Million (2017-2022)
    • Figure 9. North America United States Non-Invasive Prenatal Testing share by Players 2022 (%)
    • Figure 10. North America United States Non-Invasive Prenatal Testing share by Players (Top 3) 2022(%)
    • Figure 11. North America United States Non-Invasive Prenatal Testing share by Players (Top 5) 2022(%)
    • Figure 12. BCG Matrix for key Companies
    • Figure 13. GE Healthcare (United States) Revenue, Net Income and Gross profit
    • Figure 14. GE Healthcare (United States) Revenue: by Geography 2022
    • Figure 15. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 16. Illumina, Inc. (United States) Revenue: by Geography 2022
    • Figure 17. Thermo Fisher Scientific, Inc.(United States) Revenue, Net Income and Gross profit
    • Figure 18. Thermo Fisher Scientific, Inc.(United States) Revenue: by Geography 2022
    • Figure 19. Perkinelmer, Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 20. Perkinelmer, Inc. (United States) Revenue: by Geography 2022
    • Figure 21. Sequenom Laboratories (United States) Revenue, Net Income and Gross profit
    • Figure 22. Sequenom Laboratories (United States) Revenue: by Geography 2022
    • Figure 23. Natera Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 24. Natera Inc. (United States) Revenue: by Geography 2022
    • Figure 25. LabCorp (United States) Revenue, Net Income and Gross profit
    • Figure 26. LabCorp (United States) Revenue: by Geography 2022
    • Figure 27. Ivitae (United Status) Revenue, Net Income and Gross profit
    • Figure 28. Ivitae (United Status) Revenue: by Geography 2022
    • Figure 29. Agilent Technologies, Inc.(United States) Revenue, Net Income and Gross profit
    • Figure 30. Agilent Technologies, Inc.(United States) Revenue: by Geography 2022
    • Figure 31. Quest Diagnostics Incorporation (United States) Revenue, Net Income and Gross profit
    • Figure 32. Quest Diagnostics Incorporation (United States) Revenue: by Geography 2022
    • Figure 33. North America United States Non-Invasive Prenatal Testing: by Type USD Million (2023-2028)
    • Figure 34. North America United States Non-Invasive Prenatal Testing: by Application USD Million (2023-2028)
    • Figure 35. North America United States Non-Invasive Prenatal Testing: by Consumables USD Million (2023-2028)
    • Figure 36. North America United States Non-Invasive Prenatal Testing: by Instruments USD Million (2023-2028)
    • Figure 37. North America United States Non-Invasive Prenatal Testing: by Testing USD Million (2023-2028)
    List of companies from research coverage that are profiled in the study
    • GE Healthcare (United States)
    • Illumina, Inc. (United States)
    • Thermo Fisher Scientific, Inc.(United States)
    • Perkinelmer, Inc. (United States)
    • Sequenom Laboratories (United States)
    • Natera Inc. (United States)
    • LabCorp (United States)
    • Ivitae (United Status)
    • Agilent Technologies, Inc.(United States)
    • Quest Diagnostics Incorporation (United States)
    Select User Access Type

    Key Highlights of Report


    Oct 2023 235 Pages 66 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

    Request Sample Pages

    Budget constraints? Get in touch with us for special pricing


    Check Discount Now
    United States United States Non-Invasive Prenatal Testing Market Quantitative research analysis
    United States United States Non-Invasive Prenatal Testing Market Qualitative Industry Analysis
    DOWNLOAD SAMPLE PDF

    Talk to Our Experts

    Want to Customize Study?


    "We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

    Make an Enquiry Now

    Frequently Asked Questions (FAQ):

    The key segments that are playing vital role in United States Non-Invasive Prenatal Testing Market are by type [High & Average Risk and Low Risk], by end use application [0-12 weeks, 13-24 weeks and 25-36 weeks].
    The United States Non-Invasive Prenatal Testing Market is gaining popularity and expected to see strong valuation by 2028.
    • Increasing Incidence of Chromosome Syndrome and Genetic Abnormalities
    • Rising Healthcare Expenditure
    • Growing Demand for Early and Non-Invasive Fetal Testing Procedures
    • High Number of Reported Late Pregnancies.

    Know More About United States United States Non-Invasive Prenatal Testing Market Report?

    Have a Query? Click Here

    Other Related Reports

    Clinical Reference Laboratory Comprehensive Study by Type (Human & Tumor Genetics, Clinical Chemistry, Medical Microbiology & Cytology, Esoteric Tests), Application (Bioanalytical & Lab Chemistry Ser...
    $ 3800
    Imaging CRO Services Market Report Comprehensive Study by Technology (Decentralized and Remote Trials, Wearable Technology, Biostimulation, Others), Phase (Phase 0, Phase I, Phase II, Phase III, Pha...
    $ 3800
    Kidney Stone Comprehensive Study by Stone Type (Calcium Oxalate Stones, Uric Acid, Struvite Kidney Stones, Cystine Stones, Calcium Phosphate Stones), Treatment Type (Medications, Extracorporeal Shock...
    $ 3800
    Dental Industry Comprehensive Study by Application (Maintaining Oral Health, Pain Management, Enhancing Aesthetics, Diagnosis and Treatment of Oral Diseases, Others), Offering (Service (Preventive Se...
    $ 3800
    COVID-19 Sample Collection Kits- Comprehensive Study by Application (Research Organization, Laboratories, Hospitals and Clinics, Resedential), Sample Type (Swabs (Nasopharyngeal, Oropharyngeal, Nasal...
    $ 3800
    Ear Health Comprehensive Study by Application (Hearing Loss Treatment, Balance Disorders Treatment, Ear Infection Treatment, Tinnitus Management, Others), Product Type (Hearing Aids, Hearing Implants...
    $ 3800